Asensus Surgical Inc (AMEX:ASXC)
$ 0.26 -0.0015 (-0.57%) Market Cap: 70.81 Mil Enterprise Value: 68.27 Mil PE Ratio: 0 PB Ratio: 5.42 GF Score: 39/100

Transenterix Inc Corporate Analyst Meeting Transcript

Feb 23, 2021 / 04:00PM GMT
Release Date Price: $4.51 (-16.64%)
Anthony Fernando
TransEnterix, Inc. - President, CEO & Director

Good morning, and thank you for joining us. Our goal for today is to share our vision for the future of surgery and how we plan to deliver on that vision.

Up to this point, you have known us as a robotics company. However, we believe that robotics as a stand-alone technology has limited application over the long term. Robotic-assisted surgery has been around for decades, but adoption is still low. What that tells us is that patients, surgeons and hospitals need more than a robot.

We believe that the future of surgery will bring machine vision, augmented intelligence and deep learning capabilities throughout the surgical experience. The future of surgery is the evolution from robotic-assisted surgery to digital surgery, and we intend to deliver on this future.

Before we dive into the future, I want to quickly walk through our journey. Over a relatively short period of time, we have made tremendous progress as a company. In late 2017, we became the first soft tissue abdominal robotic platform to get FDA

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot